by G3 Group | News and Updates, Research
We’re excited to announce our new groundbreaking research projects focused on accelerating answers for people living with Charcot Marie Tooth disease. These innovative studies push beyond traditional approaches, targeting the biology of CMT in bold new ways — with the... by Teresa Carroll | News and Updates
The TIN CUP for CMT Therapies for Inherited Neuropathies (TIN) is a fully accredited 501(C)3 nonprofit whose sole focus is dedicated to identifying and advancing research and projects that bring solutions and treatments to Charcot-Marie-Tooth patients.... by Teresa Carroll | News and Updates
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and... by Teresa Carroll | News and Updates
Erva Bayraktar, Ph.D. was recently awarded the Peripheral Nerve Society’s Laura Feltri Basic Science Fellowship at its annual meeting, held in May in Edinburgh, Scotland. This prestigious grant provides two years of funding to allow a junior scientist to... by Teresa Carroll | News and Updates
In a TIN-sponsored study newly published in the May issue of Neuromuscular Disorders (https://doi.org/10.1016/j.nmd.2025.105345) the Martini group now reports that CMT1X mice treated with Fingolimod showed improved nerve function, and the drug positively changed some... by Teresa Carroll | News and Updates
The sponsor of the study is NMD Pharma A/S. If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes you may be eligible to participate in an exciting new clinical trial. NMD Pharma, a biotechnology company, has received approval... 
